Expanding cholera serosurveillance to vaccinated populations
mBio · 2025
DOI: 10.1128/mbio.01898-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, 2025. Verfasst von Forrest K Jones und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Cholera, Antibodies, Bacterial, Cholera Vaccines, Vibrio cholerae O1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases, FIC NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Mass oral cholera vaccination campaigns targeted at subnational areas with high incidence are central to global cholera elimination efforts. Serological surveillance offers a complementary approach to address gaps in clinical surveillance in these regions. However, similar immune responses from vaccination and infection can lead to overestimates of the incidence of infection. To address this, we analyzed antibody dynamics in infected and vaccinated individuals to refine seroincidence estimation strategies for partially vaccinated populations. We tested 757 longitudinal serum samples from confirmed Vibrio cholerae O1 cases and uninfected contacts in Bangladesh as well as vaccinees from Bangladesh and Haiti, using a multiplex bead assay to measure IgG, IgM, and IgA binding to five cholera-specific antigens. Infection elicited stronger and broader antibody responses than vaccination, with rises in cholera toxin B-subunit (CTB) and toxin-coregulated pilus A (TcpA) antibodies uniquely associated with infection. Previously proposed random forest models frequently misclassified vaccinated individuals as recently infected (over 20% at some time points) during the first 4 months post-vaccination. To address this, we developed new random forest models incorporating vaccinee data, which kept false-positive rates among vaccinated (1%) and unvaccinated (6%) individuals low without a significant loss in sensitivity. Simulated serosurveys demonstrated that unbiased seroincidence estimates could be achieved within 21 days of vaccination campaigns by ascertaining the vaccination status of participants or applying updated models. These approaches to overcome biases in serological surveillance enable reliable seroincidence estimation even in areas with recent vaccination campaigns enhancing the utility of serological surveillance as an epidemiologic tool in moderate-to-high cholera incidence settings. IMPORTANCE Serological surveillance can improve how we monitor cholera in high-burden areas where clinical surveillance is limited. However, vaccination can produce immune responses similar to infection, leading to overestimates in seroincidence. This study extends seroincidence estimation techniques using machine learning models to partially vaccinated populations. We analyzed antibody dynamics from vaccinated and infected individuals to develop methods that reduce the misclassification of vaccinated individuals as recently infected. These methods enable reliable seroincidence estimates in areas with recent vaccination campaigns, providing a step toward better epidemiologic monitoring in the context of global cholera control initiatives. Studies in other populations are needed to further validate our results and understand their generalizability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
- Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
- Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Zanmi Lasante, Port au Prince, Haiti.
- Department of Biochemistry and Molecular Biology, Mawlana Bhashani Science and Technology University, Santosh, Tangail, Bangladesh.
- Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Forrest K Jones, Taufiqur R Bhuiyan, Damien M Slater, Edward T Ryan, Richelle C Charles, Daniel T Leung, Firdausi Qadri, Andrew S Azman
Förderung
- National Institute of Allergy and Infectious Diseases
- FIC NIH HHS
- NIAID NIH HHS
- NICHD NIH HHS
- Fogarty International Center
Zitieren
APA
Jones, F. K., Bhuiyan, T. R., Slater, D. M., Ternier, R., Hutt Vater, K. R., Khan, A. I., Chowdhury, F., Visieres, K., Biswas, R., Kamruzzaman, M., Ryan, E. T., Calderwood, S. B., LaRocque, R. C., Charles, R. C., Leung, D. T., Lessler, J., Ivers, L. C., Qadri, F., Harris, J. B., & Azman, A. S. (2025). Expanding cholera serosurveillance to vaccinated populations. mBio. https://doi.org/10.1128/mbio.01898-25
Vancouver
Jones FK, Bhuiyan TR, Slater DM, Ternier R, Hutt Vater KR, Khan AI, et al. Expanding cholera serosurveillance to vaccinated populations. mBio. 2025. doi:10.1128/mbio.01898-25
BibTeX
@article{Jones2025,
author = {Jones, Forrest K and Bhuiyan, Taufiqur R and Slater, Damien M and Ternier, Ralph and Hutt Vater, Kian Robert and Khan, Ashraful I and Chowdhury, Fahima and Visieres, Kennia and Biswas, Rajib and Kamruzzaman, Mohammad and Ryan, Edward T and Calderwood, Stephen B and LaRocque, Regina C and Charles, Richelle C and Leung, Daniel T and Lessler, Justin and Ivers, Louise C and Qadri, Firdausi and Harris, Jason B and Azman, Andrew S},
title = {Expanding cholera serosurveillance to vaccinated populations},
journal = {mBio},
year = {2025},
doi = {10.1128/mbio.01898-25}
}
EUVIMED